Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
NFĸB signaling drives myocardial injury via CCR2+ macrophages in a preclinical model of arrhythmogenic cardiomyopathy
Stephen P. Chelko, … , Kory Lavine, Jeffrey E. Saffitz
Stephen P. Chelko, … , Kory Lavine, Jeffrey E. Saffitz
Published April 2, 2024
Citation Information: J Clin Invest. 2024;134(10):e172014. https://doi.org/10.1172/JCI172014.
View: Text | PDF | Corrigendum
Research Article Cardiology Immunology Article has an altmetric score of 7

NFĸB signaling drives myocardial injury via CCR2+ macrophages in a preclinical model of arrhythmogenic cardiomyopathy

  • Text
  • PDF
Abstract

Nuclear factor κ-B (NFκB) is activated in iPSC-cardiac myocytes from patients with arrhythmogenic cardiomyopathy (ACM) under basal conditions, and inhibition of NFκB signaling prevents disease in Dsg2mut/mut mice, a robust mouse model of ACM. Here, we used genetic approaches and single-cell RNA-Seq to define the contributions of immune signaling in cardiac myocytes and macrophages in the natural progression of ACM using Dsg2mut/mut mice. We found that NFκB signaling in cardiac myocytes drives myocardial injury, contractile dysfunction, and arrhythmias in Dsg2mut/mut mice. NFκB signaling in cardiac myocytes mobilizes macrophages expressing C-C motif chemokine receptor-2 (CCR2+ cells) to affected areas within the heart, where they mediate myocardial injury and arrhythmias. Contractile dysfunction in Dsg2mut/mut mice is caused both by loss of heart muscle and negative inotropic effects of inflammation in viable muscle. Single nucleus RNA-Seq and cellular indexing of transcriptomes and epitomes (CITE-Seq) studies revealed marked proinflammatory changes in gene expression and the cellular landscape in hearts of Dsg2mut/mut mice involving cardiac myocytes, fibroblasts, and CCR2+ macrophages. Changes in gene expression in cardiac myocytes and fibroblasts in Dsg2mut/mut mice were dependent on CCR2+ macrophage recruitment to the heart. These results highlight complex mechanisms of immune injury and regulatory crosstalk between cardiac myocytes, inflammatory cells, and fibroblasts in the pathogenesis of ACM.

Authors

Stephen P. Chelko, Vinay R. Penna, Morgan Engel, Emily A. Shiel, Ann M. Centner, Waleed Farra, Elisa N. Cannon, Maicon Landim-Vieira, Niccole Schaible, Kory Lavine, Jeffrey E. Saffitz

×

Figure 2

Blocking activation of NFκB signaling in cardiac myocytes mitigates myocardial injury and arrhythmias and preserves cardiac function in Dsg2mut/mut mice.

Options: View larger image (or click on image) Download as PowerPoint
Blocking activation of NFκB signaling in cardiac myocytes mitigates myoc...
(A) Representative trichrome-stained hearts from mice at 16 weeks of age (16 wk). Scale bars: 1 mm. (B) Percent (%) fibrosis at 16 wk; WT (n = 18), Dsg2mut/mut (n = 15), Dsg2mut/mut × IκBαΔN (n = 17), and Dsg2mut/mut × Ccr2–/– mice (n = 22). (C) Representative echocardiographs from 16 wk mice; yellow scale bar: 6 mm. (D) Percent left ventricular ejection fraction (%LVEF). Note, preserved cardiac function in Dsg2mut/mut × IκBαΔN mice. WT (n = 49), Dsg2mut/mut (n = 30), Dsg2mut/mut × IκBαΔN (n = 15), and Dsg2mut/mut × Ccr2–/– mice (n = 15). *P < 0.05 any cohort versus WT; †P < 0.05 any cohort versus Dsg2mut/mut; ‡P < 0.05 Dsg2mut/mut × Ccr2–/– versus Dsg2mut/mut × IκBαΔN mice; using 1-way ANOVA with Tukey’s posthoc analysis. (E) Representative ECGs from 16 wk mice. Premature ventricular contractions (PVCs) are noted by red arrows. (F and G) QRS duration (QRSd) and percent PVCs (% PVCs), respectively, obtained from signal averaged ECGs. QRSd: WT (n = 49), Dsg2mut/mut (n = 27), Dsg2mut/mut × IκBαΔN (n = 15), and Dsg2mut/mut × Ccr2–/– mice (n = 14). %PVCs: WT (n = 49), Dsg2mut/mut (n = 30), Dsg2mut/mut × IκBαΔN (n = 15), and Dsg2mut/mut × Ccr2–/– mice (n = 15). Data presented as mean ± SEM; *P < 0.05 any cohort versus WT; †P < 0.05 any cohort versus Dsg2mut/mut; ‡P < 0.05 Dsg2mut/mut × Ccr2–/– versus. Dsg2mut/mut × IκBαΔN mice; using 1-way ANOVA with Tukey’s post hoc analysis.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 10 X users
On 1 Facebook pages
19 readers on Mendeley
See more details